KAI Pharmaceuticals, Inc. Acquires Patents from Progen Pharmaceuticals Limited, Broadening KAI's Intellectual Property Estate Covering Peptide-Based Therapies
Published: Jun 30, 2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the acquisition of an extensive collection of issued and pending patents from Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq:PGLA), a globally focused biotechnology company. The patents claim compositions and methods related to transporter molecules that can deliver compounds, including peptides such as those being developed in the KAI pipeline, across biological membranes and into cells. Terms of the agreement were not disclosed.